



EBMT Centre Identification Code (CIC): _____
Hospital Unique Patient Number (UPN): _____
Patient Number in EBMT Registry: _____

Treatment Type ☐ HCT ☐ CT ☐ IST ☐ Other
Treatment Date ____/____/____ (YYYY/MM/DD)

NON-INDICATION DIAGNOSIS

Date of diagnosis: ____/____/____ (YYYY/MM/DD)

Classification:

☐ Acute leukaemias
☐ Autoimmune disorders
☐ Bone marrow failure syndromes including aplastic anaemia (BMF incl. AA)
☐ Chronic leukaemias
☐ Haemoglobinopathies
☐ Lymphomas
☐ MDS/MPN overlap syndromes
☐ Myelodysplastic neoplasms (MDS)
☐ Myeloproliferative neoplasms (MPN)
☐ Plasma cell neoplasms (PCN)
☐ Solid tumours

Acute leukaemias

Classification:

☐ Acute myeloid leukaemia (AML)
☐ Precursor lymphoid neoplasm (ALL)
☐ Other acute leukaemia

Acute Myeloid Leukaemias

AML with myelodysplasia related changes?

☐ No

☐ Yes; **Was there a previous diagnosis of MDS, MPN or MDS/MPN?** ☐ No ☐ Yes (complete the respective diagnosis form in addition to the current form)

☐ Unknown

Therapy related myeloid neoplasia (old "secondary acute leukaemia")? ☐ No

*Related to prior treatment but **not** after a previous diagnosis of MDS, MPN or MDS/MPN*

☐ Yes (complete the respective diagnosis form in addition to the current form)

☐ Unknown

(If therapy related myeloid neoplasia, is Yes)

Is this a donor cell leukaemia? ☐ No ☐ Yes

☐ Not applicable (no previous allo HCT)

☐ Unknown

Autoimmune disorders

Classification:

☐ **Connective tissue:**

- ☐ Systemic sclerosis (SSc, scleroderma)

SSc type:

- ☐ diffuse cutaneous
☐ limited cutaneous
☐ SSc sine scleroderma
☐ Other SSc type; specify: _____

- ☐ Systemic lupus erythematosus (SLE)
☐ Mixed connective tissue disease (MCTD)
☐ Polymyositis/Dermatomyositis (PM/DM)
☐ Sjögren syndrome
☐ Antiphospholipid syndrome
☐ Other connective tissue disease; specify: _____

☐ **Vasculitis:**

- ☐ Granulomatosis with polyangiitis (GPA); *formerly Wegener granulomatosis*
☐ Classical polyarteritis nodosa
☐ Microscopic polyarteritis nodosa
☐ Eosinophilic granulomatosis with polyangiitis (EGPA); *formerly Churg-Strauss*
☐ Behçet syndrome
☐ Takayasu arteritis
☐ Other vasculitis; specify: _____

☐ **Arthritis:**

- ☐ Adult onset stills disease (AOOSD)
☐ Rheumatoid arthritis
☐ Psoriatic arthritis/psoriasis
☐ Juvenile idiopathic arthritis (JIA), systemic (Still's disease)
☐ Juvenile idiopathic arthritis (JIA), articular
 ☐ oligoarticular onset
 ☐ polyarticular onset
☐ Other juvenile idiopathic arthritis; specify: _____
☐ Other arthritis; specify: _____

Autoimmune disorders

Classification (continued):

☐ **Neurological diseases:**

- ☐ Multiple sclerosis
- ☐ Myasthenia gravis
- ☐ Chronic inflammatory demyelinating polyneuropathy (CIDP)
- ☐ Neuromyelitis optica (NMO) or NMO spectrum disorders (NMOSD)
- ☐ Other autoimmune neurological disorder; specify: _____

☐ **Haematological diseases:**

- ☐ Idiopathic thrombocytopenic purpura (ITP)
- ☐ Haemolytic anaemia
- ☐ Evans syndrome
- ☐ Autoimmune lymphoproliferative syndrome (primary diagnosis, not subsequent to transplant)
- ☐ Other haematological autoimmune disease; specify: _____

☐ **Inflammatory bowel diseases:**

- ☐ Celiac disease
- ☐ Crohn's disease
- ☐ Ulcerative colitis
- ☐ Other autoimmune bowel disease; specify: _____

☐ **Other autoimmune/autoinflammatory diseases:**

- ☐ Insulin-dependent diabetes mellitus (IDDM)
- ☐ VEXAS syndrome
- ☐ Other autoimmune disease; specify: _____

Only for VEXAS syndrome:

Which form of VEXAS syndrome: ☐ Without concurrent MDS
☐ With concurrent MDS (**Complete MDS diagnosis form in addition to the current form**)
☐ Unknown

How was the VEXAS diagnosis made: ☐ Clinical diagnosis only
☐ Confirmed UBA1 mutation (e.g. Met41)
☐ Bone marrow features (e.g. vacuoles, dysplasia)
☐ Other method of VEXAS diagnosis, specify _____
☐ Unknown

Bone marrow failure syndromes (BMF) incl. aplastic anaemia (AA)

Classification:

☐ Acquired:

☐ Aplastic anaemia (AA) Severity of Aplastic Anaemia (AA): ☐ Moderate ☐ Severe ☐ Very Severe	Etiology: ☐ Secondary to hepatitis ☐ Secondary to toxin/other drug ☐ Idiopathic ☐ Other; specify: _____
☐ Pure red cell aplasia (non-congenital PRCA)	
☐ PNH PNH presentation: ☐ Haemolytic ☐ Aplastic ☐ Thrombotic ☐ Other; specify: _____	
☐ Pure white cell aplasia	
☐ Amegakaryocytosis / Thrombocytopenia (non-congenital)	
☐ Other acquired cytopenic syndrome; specify: _____	

☐ Genetic:

☐ Amegakaryocytosis / Thrombocytopenia (congenital)																																	
☐ Fanconi anaemia <table> <tr> <td>Mutated gene:</td> <td>☐ FANCA</td> <td>☐ FANCM</td> </tr> <tr> <td></td> <td>☐ FANCB</td> <td>☐ FANCN (PALB2)</td> </tr> <tr> <td></td> <td>☐ FANCC</td> <td>☐ FANCO (RAD51C)</td> </tr> <tr> <td></td> <td>☐ FANCD1 (BRCA2)</td> <td>☐ FANCP (SLX4)</td> </tr> <tr> <td></td> <td>☐ FANCD2</td> <td>☐ FANCQ (XPF)</td> </tr> <tr> <td></td> <td>☐ FANCE</td> <td>☐ FANCS (BRCA1)</td> </tr> <tr> <td></td> <td>☐ FANCF</td> <td>☐ FANCT (UBE2T)</td> </tr> <tr> <td></td> <td>☐ FANCG</td> <td>☐ FANCU (XRCC2)</td> </tr> <tr> <td></td> <td>☐ FANCI</td> <td>☐ FANCV (REV7)</td> </tr> <tr> <td></td> <td>☐ FANCJ (BRIP1)</td> <td>☐ FANCW (RFWD3)</td> </tr> <tr> <td></td> <td>☐ FANCL</td> <td>☐ Other; specify: _____</td> </tr> </table>	Mutated gene:	☐ FANCA	☐ FANCM		☐ FANCB	☐ FANCN (PALB2)		☐ FANCC	☐ FANCO (RAD51C)		☐ FANCD1 (BRCA2)	☐ FANCP (SLX4)		☐ FANCD2	☐ FANCQ (XPF)		☐ FANCE	☐ FANCS (BRCA1)		☐ FANCF	☐ FANCT (UBE2T)		☐ FANCG	☐ FANCU (XRCC2)		☐ FANCI	☐ FANCV (REV7)		☐ FANCJ (BRIP1)	☐ FANCW (RFWD3)		☐ FANCL	☐ Other; specify: _____
Mutated gene:	☐ FANCA	☐ FANCM																															
	☐ FANCB	☐ FANCN (PALB2)																															
	☐ FANCC	☐ FANCO (RAD51C)																															
	☐ FANCD1 (BRCA2)	☐ FANCP (SLX4)																															
	☐ FANCD2	☐ FANCQ (XPF)																															
	☐ FANCE	☐ FANCS (BRCA1)																															
	☐ FANCF	☐ FANCT (UBE2T)																															
	☐ FANCG	☐ FANCU (XRCC2)																															
	☐ FANCI	☐ FANCV (REV7)																															
	☐ FANCJ (BRIP1)	☐ FANCW (RFWD3)																															
	☐ FANCL	☐ Other; specify: _____																															
☐ Diamond-Blackfan anaemia (congenital PRCA)																																	
☐ Shwachman-Diamond syndrome																																	
☐ Dyserythropoietic anaemia																																	
☐ Dyskeratosis congenita																																	
☐ Congenital sideroblastic anaemia (CSA)																																	
☐ Other congenital anaemia; specify: _____																																	

Chronic leukaemias

Classification (WHO 2022):

☐ Chronic myeloid leukaemia (CML)
☐ Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) / Richter transformation
☐ Prolymphocytic (PLL) and other chronic leukaemias

MDS/MPN overlap syndromes

Classification (WHO 2022):

☐ Chronic myelomonocytic leukaemia (CMML, CMML)
☐ MDS/MPN with SF3B1 mutation and thrombocytosis
☐ MDS/MPN with neutrophilia (Atypical CML BCR-ABL1-negative)
☐ MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
☐ MDS/MPN not otherwise specified (NOS)

MDS

Therapy related MDS (Secondary origin)? ☐ No

☐ Yes, disease related to prior exposure to therapeutic drugs or radiation

☐ Unknown

(If therapy related MDS, is Yes)

Is this a donor derived myeloid neoplasm (DDMN)? ☐ No

☐ Yes

☐ Not applicable (no previous allo HCT)

☐ Unknown

Myeloproliferative neoplasms (MPN)

Classification at treatment (WHO 2022):

☐ Primary myelofibrosis
☐ Polycythaemia vera (PV)
☐ Essential or primary thrombocythaemia (ET)
☐ Juvenile myelomonocytic leukaemia (JCMMoL, JMML, JCML, JCMML)
☐ Hyper eosinophilic syndrome (HES)
☐ Chronic eosinophilic leukaemia (CEL)
☐ Chronic neutrophilic leukaemia (CNL)
☐ Aggressive systemic mastocytosis
☐ Systemic mastocytosis with an associated haematologic neoplasm (SM-AHN)
☐ Mast cell leukaemia
☐ Mast cell sarcoma
☐ MLN-TK with FGFR1 rearrangement
☐ MLN-TK with PDGFRA rearrangement
☐ MLN-TK with PDGFRB rearrangement
☐ MLN-TK with JAK2 rearrangement
☐ MLN-TK with FLT3 rearrangement
☐ MLN-TK with ETV6::ABL1 fusion
☐ MPN not otherwise specified (NOS)
☐ Other; specify: _____

Plasma cell neoplasms (PCN)

Classification (WHO 2022):

☐ Plasma cell (multiple) myeloma (PCM)	☐ Heavy chain and light chain	Heavy chain type: ☐ IgG ☐ IgA ☐ IgD ☐ IgE ☐ IgM (not Waldenstrom) ☐ Unknown	Light chain type: ☐ Kappa ☐ Lambda ☐ Unknown
	☐ Light chain only		
	☐ Non-secretory		
	☐ Unknown		
☐ Plasma cell leukaemia			
☐ Solitary plasmacytoma of bone			
☐ Immunoglobulin-related (AL) amyloidosis			
☐ POEMS (Polyneuropathy, Organomegaly, Endocrinopathy/Edema, Monoclonal-protein, Skin changes)			
☐ Monoclonal immunoglobulin deposition disease			
☐ Other; specify: _____			

Lymphomas

Classification:

☐ B-cell non-Hodgkin lymphoma (NHL)
☐ T-cell non-Hodgkin lymphoma (NHL)
☐ Hodgkin lymphoma
☐ Immunodeficiency-associated lymphoproliferative disorder (incl. PTLD)
☐ Other; specify _____

Lymphomas B-Cell Non-Hodgkin Lymphomas (NHL)

Sub-Classification: Mature B-cell neoplasms

☐ Splenic B-cell lymphomas and leukaemias ☐ Splenic marginal zone lymphoma ☐ Splenic diffuse red pulp small B-cell lymphoma
☐ Lymphoplasmacytic lymphoma ☐ IgM-LPL/ Waldenström Macroglobulinaemia (WM) type ☐ Non-WM type LPL
☐ Marginal zone lymphoma ☐ Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue ☐ Primary cutaneous marginal zone lymphoma ☐ Nodal marginal zone lymphoma ☐ Paediatric marginal zone lymphoma
☐ Follicular lymphoma ☐ Classical follicular lymphoma (cFL) ☐ Follicular large B-cell lymphoma (FLBL) ☐ FL with uncommon features (uFL)
☐ Paediatric-type follicular lymphoma
☐ Duodenal-type follicular lymphoma
☐ Cutaneous follicle centre lymphoma
☐ Mantle cell lymphoma ☐ Mantle cell lymphoma ☐ Leukaemic non-nodal mantle cell lymphoma
☐ Transformations of indolent B-cell lymphomas

Lymphomas

B-Cell Lymphoid Proliferation and Lymphomas

Sub-Classification: Mature B-cell neoplasms

- ☐ Large B-cell lymphomas
 - ☐ Diffuse large B-cell lymphoma, NOS
 - ☐ Germinal centre B- cell-like subtype (GCB)
 - ☐ Activated B-cell-like subtype (ABC)
 - ☐ T-cell/histiocyte-rich large B-cell lymphoma
 - ☐ Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC and BCL2 rearrangements
 - ☐ ALK-positive large B-cell lymphoma
 - ☐ Large B-cell lymphoma with IRF4 rearrangement
 - ☐ High-grade B-cell lymphoma with 11q aberrations
 - ☐ Lymphomatoid granulomatosis
 - ☐ EBV-positive diffuse large B-cell lymphoma
 - ☐ Diffuse large B-cell lymphoma associated with chronic inflammation
 - ☐ Fibrin-associated large B-cell lymphoma
 - ☐ Fluid overload-associated large B-cell lymphoma
 - ☐ Plasmablastic lymphoma
 - ☐ Primary large B-cell lymphoma of immune-privileged sites
 - ☐ Primary large B-cell lymphoma of the CNS
 - ☐ Primary large B-cell lymphoma of the vitreoretina
 - ☐ Primary large B-cell lymphoma of the testis
 - ☐ Primary cutaneous diffuse large B-cell lymphoma, leg type
 - ☐ Intravascular large B-cell lymphoma
 - ☐ Primary mediastinal large B-cell lymphoma
 - ☐ Mediastinal grey zone lymphoma
 - ☐ High-grade B-cell lymphoma, NOS
- ☐ Burkitt lymphoma
 - ☐ EBV-positive BL
 - ☐ EBV-negative BL
- ☐ KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas
 - ☐ KSHV/HHV8-positive diffuse large B-cell lymphoma
 - ☐ KSHV/HHV8-positive germinotropic lymphoproliferative disorder

Lymphomas

T-cell and NK-cell Lymphoid Proliferation and Lymphomas

Sub-Classification: Mature T-cell & NK-cell Neoplasms

☐ **Mature T-cell and NK-cell leukaemias**

- ☐ T-large granular lymphocytic leukaemia
- ☐ NK-large granular lymphocytic leukaemia
- ☐ Adult T-cell leukaemia/lymphoma
- ☐ Sezary syndrome
- ☐ Aggressive NK-cell leukaemia

☐ **Primary cutaneous T-cell lymphomas**

- ☐ Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder
- ☐ Primary cutaneous acral CD8-positive lymphoproliferative disorder
- ☐ Mycosis fungoides
- ☐ Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: lymphomatoid papulosis
- ☐ Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma
- ☐ Subcutaneous panniculitis-like T-cell lymphoma
- ☐ Primary cutaneous gamma/delta T-cell lymphoma
- ☐ Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma
- ☐ Primary cutaneous peripheral T-cell lymphoma, not otherwise specified

☐ **Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas**

- ☐ Indolent T-cell lymphoma of the gastrointestinal tract
- ☐ Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract
- ☐ Enteropathy-associated T-cell lymphoma
- ☐ Monomorphic epitheliotropic intestinal T-cell lymphoma
- ☐ Intestinal T-cell lymphoma not otherwise specified

☐ **Hepatosplenic T-cell lymphoma**

☐ **Anaplastic large cell lymphomas**

- ☐ ALK-positive anaplastic large cell lymphoma
- ☐ ALK-negative anaplastic large cell lymphoma
- ☐ Breast implant-associated anaplastic large cell lymphoma

Lymphomas

T-Cell Non-Hodgkin Lymphomas (NHL)

Sub-Classification: Mature T-cell & NK-cell Neoplasms

☐ **Nodal T-follicular helper (TFH) lymphomas**

- ☐ Nodal TFH cell lymphoma, angioimmunoblastic-type
- ☐ Nodal TFH cell lymphoma, follicular type
- ☐ Nodal TFH cell lymphoma, not otherwise specified

☐ **Peripheral T-cell lymphoma, not otherwise specified**

☐ **EBV-positive NK/T-cell lymphomas**

- ☐ EBV-positive nodal T- and NK-cell lymphoma
- ☐ Extranodal NK/T-cell lymphoma

☐ **EBV-positive T- and NK-cell lymphoid proliferations and lymphomas of childhood**

- ☐ Severe mosquito bite allergy
- ☐ Hydroa vacciniforme lymphoproliferative disorder
- ☐ Systemic chronic active EBV disease
- ☐ Systemic EBV-positive T-cell lymphoma of childhood

Lymphomas

Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)

Sub-Classification: Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)

☐ Lymphoproliferative disease associated with primary immune disorder

☐ Lymphoma associated with HIV infection

☐ Post-transplant lymphoproliferative disorder (PTLD)

☐ Non-destructive PTLD

- ☐ Plasmacytic hyperplasia PTLD
- ☐ Infectious mononucleosis PTLD
- ☐ Florid follicular hyperplasia PTLD

☐ Polymorphic PTLD

☐ Monomorphic PTLD

- ☐ B-cell type
- ☐ T-/NK-cell type

☐ Classical Hodgkin lymphoma PTLD

☐ Other immunodeficiency-associated lymphoproliferative disorder



EBMT Centre Identification Code (CIC): ____
Hospital Unique Patient Number (UPN): ____
Patient Number in EBMT Registry: ____

Treatment Type ☐ HCT ☐ CT ☐ IST ☐ Other
Treatment Date ____/____/____ (YYYY/MM/DD)

LYMPHOMAS

Hodgkin Lymphomas

DISEASE

Sub-Classification: Hodgkin Lymphomas

- | |
|---|
| ☐ Nodular lymphocyte predominant |
| ☐ Classical predominant; lymphocyte-rich |
| ☐ Classical predominant; nodular sclerosis |
| ☐ Classical predominant; mixed cellularity |
| ☐ Classical predominant; lymphocyte-depleted |
| ☐ Classical predominant; NOS |
| ☐ Other Hodgkin lymphoma; specify: _____ |

Haemoglobinopathy

Classification:

- ☐ Thalassaemia
- ☐ Sickle Cell Disease
- ☐ Other Haemoglobinopathy; specify: _____

Solid tumours

Classification:

- ☐ Bone sarcoma (excluding Ewing sarcoma/PNET)
- ☐ Breast
- ☐ Central nervous system tumours (including CNS/PNET)
- ☐ Ewing sarcoma (ES) / PNET, extraskeletal
- ☐ Ewing sarcoma (ES) / PNET, skeletal
- ☐ Ewing sarcoma (ES)/PNET, not classified
- ☐ Germ cell tumour, extragonadal only
- ☐ Germ cell tumour, gonadal
- ☐ GI tract and Hepatopancreatic cancers
- ☐ Kidney cancer excluding Wilm's tumour
- ☐ Lung cancer, small cell
- ☐ Lung cancer, non small cell (NSCLC)
- ☐ Medulloblastoma
- ☐ Melanoma
- ☐ Nasopharyngeal carcinoma
- ☐ Neuroblastoma
- ☐ Ovarian (carcinoma)
- ☐ Prostate
- ☐ Retinoblastoma
- ☐ Rhabdomyosarcoma
- ☐ Soft tissue sarcoma (excluding Rhabdo and extraskeletal ES)
- ☐ Thymoma
- ☐ Wilm's tumour
- ☐ Other solid tumor; specify: _____